20th April 2023 : Press Release Nottingham, UK, 20th April: Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced in January this year, the state-of-the-art facility has benefited from a … Read more
Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route.Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, prophylactics) Systemic delivery by absorption into the bloodstream (e.g. for fast … Read more
January 31st 2023 : Newsletter The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have in store for ourselves and … Read more
18th January 2023 Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has begun construction work for its new Development and GMP Manufacturing headquarters in Nottingham, UK. Working in close collaboration with its principal Design and Build contractor, T-SQUARED the team officially broke ground on the … Read more
29th November 2022 – Press Release & Newsletter Upperton Pharma Solutions Appoints T-SQUARED for Design and Build of New Development and Manufacturing Facility Upperton Pharma Solutions, a leading UK contract development and manufacturing organisation (CDMO), is delighted to announce that it has appointed T-SQUARED, UK based company, as the principal Design and Build contractor for … Read more
November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product … Read more
Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of the powder exiting the device, … Read more
The Benefits of Powder Characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties will have a direct impact … Read more
21st April 2022 – Press Release Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to … Read more
5th April 2022 – Press Release Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage formulations. Drug developers seeking to … Read more
Driven by experts, led by science
Integrated CDMO services
By Development Stage
Development Platforms
Route of delivery
About Us
Our Approach
Events
Resources
Policies
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA, UK. Phone: +44 (0) 115 855 7050 Email: contact@upperton.com
Copyright © 2025 Upperton Limited. Registration number: 03833301. Registered office address: Albert Einstein Centre, Nottingham Science Park, Nottingham, NG7 2TN. Registered in England. All rights reserved.
Speak with our team of experts and set up a discovery call to discuss your project in more detail.